Antibodies to OPGL
View Patent ↗Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
1. An isolated antibody comprising:
a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 2; and
b) a light chain comprising the amino acid sequence of SEQ ID NO: 4.
2. An isolated antibody consisting of:
a) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 2; and
b) a light chain consisting of the amino acid sequence of SEQ ID NO: 4.
3. An isolated antibody comprising:
a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 13; and
b) a light chain comprising the amino acid sequence of SEQ ID NO: 14.
4. The antibody of claim 3 , wherein the heavy chain and the light chain are connected by a flexible linker to form a single-chain antibody.
5. The antibody of claim 4 , which is a single-chain Fv antibody.
6. The antibody of claim 3 , which is a Fab antibody.
7. The antibody of claim 3 , which is a Fab′ antibody.
8. The antibody of claim 3 , which is a F(ab′) 2 antibody.
9. The antibody of claim 3 , which is fully human.
10. The antibody of claim 3 , wherein the antibody inhibits binding of a human osteoprotegerin ligand (OPGL) to an osteoclast differentiation and activation receptor (ODAR).
11. An isolated antibody comprising:
a) a heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 13; and
b) a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 14.
12. The antibody of claim 11 , wherein the heavy chain and the light chain are connected by a flexible linker to form a single-chain antibody.
13. The antibody of claim 12 , which is a single-chain Fv antibody.
14. The antibody of claim 11 , which is a Fab antibody.
15. The antibody of claim 11 , which is a Fab′ antibody.
16. The antibody of claim 11 , which is a F(ab′) 2 antibody.
17. The antibody of claim 11 , which is fully human.
18. The antibody of claim 11 , wherein the antibody inhibits binding of a human osteoprotegerin ligand (OPGL) to an osteoclast differentiation and activation receptor (ODAR).
19. A pharmaceutical composition comprising the antibody of any one of claims 1 , 2 , 3 , and 11 .
20. The pharmaceutical composition of claim 19 , wherein the composition comprises an acetate buffer.
21. The pharmaceutical composition of claim 19 , wherein the composition comprises polysorbate.
22. The pharmaceutical composition of claim 19 , wherein the composition comprises sorbitol.
23. The pharmaceutical composition of claim 19 , wherein the composition comprises acetate and sorbitol.
24. The pharmaceutical composition of claim 19 , wherein the composition is contained in a prefilled syringe.
25. The pharmaceutical composition of claim 19 , wherein the composition is in unit dose form.